Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


13.11.2017

1 AJR Am J Roentgenol
4 BJU Int
2 BMC Cancer
1 Br J Cancer
1 Cancer Lett
1 Clin Cancer Res
1 Clin Med Insights Oncol
4 Eur Urol
3 Int J Cancer
1 Int J Oncol
5 Int J Radiat Oncol Biol Phys
1 J Natl Cancer Inst
4 J Nucl Med
4 Nat Rev Urol
1 Oncol Rep
1 PLoS One
1 Prog Urol
7 Prostate
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SHERIDAN AD, Nath SK, Syed JS, Aneja S, et al
    Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
    AJR Am J Roentgenol. 2017 Nov 7:1-11. doi: 10.2214/AJR.17.18516.
    PubMed     Text format     Abstract available


    BJU Int

  2. KIRK PS, Borza T, Shahinian VB, Caram MEV, et al
    The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer.
    BJU Int. 2017 Nov 10. doi: 10.1111/bju.14075.
    PubMed     Text format     Abstract available

  3. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    PubMed     Text format    

  4. CHALFIN HJ, Pienta KJ, Gorin MA
    Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.
    BJU Int. 2017;120.
    PubMed     Text format    

  5. LOEB S
    Educational intervention in prostate cancer.
    BJU Int. 2017;120.
    PubMed     Text format    


    BMC Cancer

  6. ENDZELINS E, Berger A, Melne V, Bajo-Santos C, et al
    Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.
    BMC Cancer. 2017;17:730.
    PubMed     Text format     Abstract available

  7. JIANN BP
    Does hair dye use really increase the risk of prostate cancer?
    BMC Cancer. 2017;17:724.
    PubMed     Text format     Abstract available


    Br J Cancer

  8. HU J, Tian J, Zhu S, Sun L, et al
    Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-beta-induced epithelial mesenchymal transition through controlling Twist1 expression.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. GONZALEZ-CHAVARRIA I, Fernandez E, Gutierrez N, Gonzalez-Horta EE, et al
    LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30672.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
    Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
    PubMed     Text format     Abstract available


    Clin Med Insights Oncol

  11. TATSUZAWA M, Ogawa R, Kinjo N, Kim S, et al
    Consequences of Different Corticosteroids on Serum Potassium and Prostate-Specific Antigen in Patients Receiving Abiraterone for Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Clin Med Insights Oncol. 2017;11:1179554917737736.
    PubMed     Text format     Abstract available


    Eur Urol

  12. CULINE S
    Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30907.
    PubMed     Text format    

  13. IBRAGIMOVA N, Zhanzak Z, Meyerbekova A, Xie Y, et al
    Re: Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Nov 4. pii: S0302-2838(17)30910.
    PubMed     Text format    

  14. SPRATT DE, Dess RT, Feng FY
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Can
    Eur Urol. 2017 Oct 27. pii: S0302-2838(17)30897.
    PubMed     Text format    

  15. MOTTET N, De Santis M, Briers E, Gillessen S, et al
    Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
    Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839.
    PubMed     Text format     Abstract available


    Int J Cancer

  16. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available

  17. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Text format     Abstract available

  18. DICKERMAN BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, et al
    Midlife metabolic factors and prostate cancer risk in later life.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31142.
    PubMed     Text format     Abstract available


    Int J Oncol

  19. XU W, Foster BA, Richards M, Bondioli KR, et al
    Characterization of prostate cancer cell progression in zebrafish xenograft model.
    Int J Oncol. 2017 Nov 6. doi: 10.3892/ijo.2017.4189.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  20. VAN DER VELDEN JM, Peters M, Verlaan JJ, Versteeg AL, et al
    Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases.
    Int J Radiat Oncol Biol Phys. 2017;99:859-866.
    PubMed     Text format     Abstract available

  21. LIM-REINDERS S, Keller BM, Al-Ward S, Sahgal A, et al
    Online Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2017;99:994-1003.
    PubMed     Text format     Abstract available

  22. BARADARAN-GHAHFAROKHI M, Amouheidari A, Shahbazi-Gahrouei D, Baradaran-Ghahfarokhi HR, et al
    Evaluation of the Effects of Prostate Radiation Therapy on Occludin Expression and Ultrasonography Characteristics of the Bladder.
    Int J Radiat Oncol Biol Phys. 2017;99:963-971.
    PubMed     Text format     Abstract available

  23. MARTELL K, Husain S, Taussky D, Angyalfi S, et al
    Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.
    Int J Radiat Oncol Biol Phys. 2017;99:895-903.
    PubMed     Text format     Abstract available

  24. KEAM SP, Caramia F, Gamell C, Paul PJ, et al
    The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort.
    Int J Radiat Oncol Biol Phys. 2017 Sep 25. pii: S0360-3016(17)33937.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  25. CONTI DV, Wang K, Sheng X, Bensen JT, et al
    Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    J Nucl Med

  26. GIESEL FL, Kopka K
    Reply: PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198176. doi: 10.2967/jnumed.117.198176.
    PubMed     Text format    

  27. CALAIS J, Czernin J, Cao M, Kishan AU, et al
    68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.201749. doi: 10.2967/jnumed.117.201749.
    PubMed     Text format     Abstract available

  28. ZHANG J, Niu G, Fan X, Lang L, et al
    Positron Emission Tomography Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198929. doi: 10.2967/jnumed.117.198929.
    PubMed     Text format     Abstract available

  29. EIBER M, Herrmann K, Calais J, Hadaschihk B, et al
    PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198119. doi: 10.2967/jnumed.117.198119.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  30. THOMA C
    Prostate cancer: No benefit of combining custirsen with cabazitaxel.
    Nat Rev Urol. 2017 Nov 8. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  31. THOMPSON J, Stricker P
    Imaging: MRI improves cost and accuracy of prostate cancer biopsy.
    Nat Rev Urol. 2017 Nov 8. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  32. THOMA C
    Prostate cancer: Treatment after ADT plus docetaxel.
    Nat Rev Urol. 2017 Nov 8. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  33. THOMA C
    Prostate cancer: Brachytherapy monotherapy is efficacious.
    Nat Rev Urol. 2017 Nov 8. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncol Rep

  34. SZYSZKA M, Tyczewska M, Milecka P, Jopek K, et al
    Effects of leptin on leptin receptor isoform expression and proliferative activity in human normal prostate and prostate cancer cell lines.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6066.
    PubMed     Text format     Abstract available


    PLoS One

  35. XIAO WJ, Zhu Y, Dai B, Ye DW, et al
    Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
    PLoS One. 2017;12:e0187887.
    PubMed     Text format     Abstract available


    Prog Urol

  36. DEFONTAINES J, Salomon L, Champy C, Cholley I, et al
    [Prostate cancer diagnostic by saturation randomized biopsy versus rigid targeted biopsy].
    Prog Urol. 2017 Nov 6. pii: S1166-7087(17)30536.
    PubMed     Text format     Abstract available


    Prostate

  37. DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
    FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
    PubMed     Text format     Abstract available

  38. NESBITT H, Worthington J, Errington RJ, Patterson LH, et al
    The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
    Prostate. 2017;77:1539-1547.
    PubMed     Text format     Abstract available

  39. SCHMIDKONZ C, Hollweg C, Beck M, Reinfelder J, et al
    99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23444.
    PubMed     Text format     Abstract available

  40. XIAO H, Wang J, Yan W, Cui Y, et al
    GLUT1 regulates cell glycolysis and proliferation in prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23448.
    PubMed     Text format     Abstract available

  41. CHENG HH, Plets M, Li H, Higano CS, et al
    Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23452.
    PubMed     Text format     Abstract available

  42. MARTINO T, Kudrolli TA, Kumar B, Salviano I, et al
    The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23455.
    PubMed     Text format     Abstract available

  43. TAT D, Kenfield SA, Cowan JE, Broering JM, et al
    Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE).
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23441.
    PubMed     Text format     Abstract available


    Radiology

  44. HECTORS SJ, Semaan S, Song C, Lewis S, et al
    Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Composition-A Hypothesis-generating Study.
    Radiology. 2017 Nov 8:170904. doi: 10.1148/radiol.2017170904.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: